BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32653671)

  • 1. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
    Gachechiladze M; Škarda J; Skanderová D; Überall I; Kolek V; Smičkova P; Vojta P; Vbrková J; Hajdúch M; Shani I; Kolář Z; Stahel R; Weder W; Rulle U; Soltermann A; Joerger M
    Lung Cancer; 2020 Sep; 147():30-38. PubMed ID: 32653671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of PD-L1 expression in combination with CD8
    Yang H; Shi J; Lin D; Li X; Zhao C; Wang Q; Zhang L; Jiang T; Zhao S; Liu X; Jia Y; Zhang Y; Cai W; Zhou C
    Cancer Med; 2018 Jan; 7(1):32-45. PubMed ID: 29168339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
    Zheng QM; Li YY; Wang YP; Li GX; Zhao MM; Sun ZG
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):643-659. PubMed ID: 37114477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
    Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients.
    Gachechiladze M; Škarda J; Kolek V; Grygárková I; Langová K; Bouchal J; Kolář Z; Baty F; Stahel R; Weder W; Soltermann A; Joerger M
    Lung Cancer; 2017 Mar; 105():31-38. PubMed ID: 28236982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8
    Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
    Front Immunol; 2021; 12():680973. PubMed ID: 34122444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).
    Tufman A; Neumann J; Manapov F; Sellmer L; Jung A; Kauffmann-Guerrero D; Kahnert K; Mertsch P; Borgmeier A; Semrau S; Rittmeyer A; Ulm B; Ulm K; Flentje M; Fietkau R; Huber RM
    Lung Cancer; 2021 Oct; 160():17-27. PubMed ID: 34371299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer.
    Zens P; Bello C; Scherz A; von Gunten M; Ochsenbein A; Schmid RA; Berezowska S
    Mod Pathol; 2022 Dec; 35(12):1848-1859. PubMed ID: 35915139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-9 in non-small cell lung cancer.
    He Y; Jia K; Dziadziuszko R; Zhao S; Zhang X; Deng J; Wang H; Hirsch FR; Zhou C
    Lung Cancer; 2019 Oct; 136():80-85. PubMed ID: 31454748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
    Gachechiladze M; Uberall I; Skanderova D; Matchavariani J; Ibrahim M; Shani I; Smickova P; Kolek V; Cierna L; Klein J; Stahel R; Joerger M; Soltermann A; Skarda J
    Lung Cancer; 2021 Jun; 156():129-135. PubMed ID: 33962766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
    He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR
    Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
    Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A
    Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
    Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.